Table 1.
Calculated IC50 and IC25 values in ten canine neoplastic cell lines following 72h of treatment with GS-343074 or GS-424044
| IC50/IC25 (nmol/L) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Drug | C-TAC | CML-1 | CML-6M | 17-CM98 | CMT-12 | CMT-27 | DEN-HSA | Abrams | D17 | 1771 |
| GS-343074 (C/1) | 21.4/8.6 | NA/36.0 | 16.8/7.0 | 90.9/10.8 | 16.4/7.4 | 11.9/5.6 | NA/NA | 55.7/12.7 | 20.0/8.2 | 18.0/7.5 |
| GS-343074 (C/10) | 48.4/17.6 | 35.9/9.2 | 146.8/26.2 | NA/24.0 | NA/34.8 | NA/21.2 | NA/28.6 | 201.4/17.2 | 30.8/13.5 | 34.5/15.0 |
| GS-424044 (C/1) | NA/NA | NA/14.2 | 236.5/68.0 | NA/15.0 | 45.4/12.6 | 27.4/37.6 | NA/NA | 324.0/112.2 | 23.3/12.0 | 106.5/16.5 |
| GS-424044 (C/10) | NA/NA | 75.1/12.0 | 336.0/155.8 | 51.0/15.0 | 261.0/62.3 | NA/149.0 | NA/NA | NA/101.8 | 54.8/14.2 | 81.0/24.0 |
NA, not achieved.
GS analogue was administered to cells in MEM supplemented with 1% (C/1) or 10% (C/10) FBS.